TITLE

Discontinuation of Primary Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic

AUTHOR(S)

Mussini, Cristina; Pezzotti, Patrizio; Govoni, Alessandra; Borghi, Vanni; Antinori, Andrea; d'Arminio Monforte, Antonella; De Luca, Andrea; Mongiardo, Nicola; Cerri, Maria Chiara; Chiodo, Francesco; Concia, Ercole; Bonazzi, Lucio; Moroni, Mauro; Ortona, Luigi; Esposito, Robert; Cossarizza, Andrea; De Rienzo, Bruno

PUB. DATE

May 2000

SOURCE

Journal of Infectious Diseases;5/1/2000, Vol. 181 Issue 5, p1635

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Examines the discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients infected with HIV-type 1 whose CD4[sup +] T cell counts have increased to 200 cells per cubic millimeter as a result of highly active antiretrovial therapy (HAART). Decline in the incidence of several serious infections; Effectiveness of HAART; Changes in the opportunistic prophylaxis study.

ACCESSION #

5377612

 

Related Articles

• Pneumocystis carinii pneumonia.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p26 

  Reports on the US Food and Drug Administration's approval on the marketing of a suspension form of atovaquone in the treatment of pneumocystis carinii pneumonia. Advantages and convenience; Dosage.

• Current management practices in the treatment of Pneumocystis carinii pneumonia (PCP). Blanchet, Kevin D. // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p116 

  Presents a dialogue on current management practices in the treatment of Pneumocystis carinii pneumonia (PCP). Prophylaxis and compliance; Treatment of mild PCP; Patient management issues.

• Pneumocystis carinii pneumonia prophylaxis reduces mortality, costs.  // Formulary;Sep95, Vol. 30 Issue 9, p544 

  Presents an abstract of the article `The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia,' by J.E. Gallant, S.M. McAvinue, R.D. Moore et al, which appeared in the 1995 issue of `Chest' periodical.

• PCP PREVENTION ALERT. Delaney, Martin // Advocate;11/19/91, Issue 590, p37 

  Reports on the medical alert received by physicians from the U.S. National Institutes of Health concerning the prevention of second bouts of Pneumocystis carinii pneumonia. Call for monthly treatments with aerosol pentamidine; Superiority of the oral use of two common antibiotics.

• RACE AND TREATMENT ACCESS.  // Advocate;6/28/94, Issue 658, p58 

  Reports on racial disparities in the administration of antiretroviral therapy and prophylactic treatment for Pneumocystis carinii pneumonia. Access to and standards of care.

• Improved Treatment For Pneumocystis. Helquist, Michael // Advocate;10/13/87, Issue 483, p23 

  Reports on the efficacy of aerosol pentamidine against pneumocystis carinii pneumonia in persons with AIDS. Absence of side effects; Reduction in average hospital stay.

• DELAYING THE ONSET OF ILLNESS. Cohan, Gary R. // Advocate;2/8/94, Issue 648, p34 

  Reports that prophylaxis against Pneumocystis carinnii infection may delay the onset of the first AIDS-related illness.

• Prophylaxis Recommendations for Pneumocystis. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;3/25/2002, Vol. 15 Issue 3, p110 

  Reports the indication of primary prophylaxis of Pneumocystis for patients with history of Pneumocystis carinii pneumonia. Efficacy of trimethoprim-sulfamethoxazole (TMP-SMX); Considerations in discontinuing primary and secondary prophylaxis; Dosage for TMP-SMX.

• Prophylaxis Failure Is Associated with a Specific Pneumocystis carinii Genotype. Hauser, Philippe M.; Sudre, Philippe; Nahimana, Aimable; Francioli, Patrick // Clinical Infectious Diseases;10/1/2001, Vol. 33 Issue 7, p1080 

  To investigate the possible association between Pneumocystis carinii types and various clinical and demographic parameters, we used molecular typing to analyze 93 bronchoalveolar lavage specimens from patients with P. carinii pneumonia (PCP). Multivariate regression analysis revealed an...

Read the Article